作者
助理經理
曾任職鋼材交易員及廣告公司主任，所以特別喜歡研究資源類及消費類股票。歡迎來電賜教或交流心得。
電話:
22776779
電郵:
alexni@phillip.com.hk
UMP HEALTHCARE HOLDINGS LTD. (722)
4651
Commentary:
|
Stock: |
UMP Healthcare Holdings Ltd. |
|
1 Month H/L: |
0.86 – 0.75 |
|
Stock Code: |
772.HK |
|
52 week H/L: |
1.212 – 0.622 |
|
Market Cap.: |
HKD 634.133M |
|
Listing date: |
27/11/2015 |
|
Stock Outstanding: |
792,666,555 shares |
|
Listing price: |
2.06 |
|
P/E (TTM): |
17.467x |
|
Chairman & CEO: |
Dr. Sun Yiu Kwong |
|
Dividend: |
0.038 |
|
Major Shareholdes: |
1. Mr. Sun Yiu Kwong – 35.52% |
|
Dividend Yield: |
4.75% |
|
|
2. Chow Tai Fook (Holding)Ltd – 15.04% |
|
|
|
|
|
3. China Resources Medical Holdings Co. Ltd. - 11.99% |
Established in 1990, UMP health care is a healthcare solution provider operating in Hong Kong as well as Macau and Mainland China. The company's business consist of: 1. Hong Kong & Macau corporate healthcare solutions, 2. Clincal healthcare services, and 3. Mainland China healthcare business.
The company released its interim result on the 24th of February, the table below briefly summarised the company's performance:
|
Business segment |
Business description |
Remarks |
|
Hong Kong & Macau Corporate healthcare solutions |
Tailored healthcare plan to corporate customers, for example, insurance companies, whom their policy holders can use the services. Also, corporations can contract the company to provide healthcare services plan to its employees.
|
Revenue increased by 1.8% from HK$122.3 million for 1HFY2021 to HK$124.5 miilion. Contributions mainly attributed by Medical services, due to number of visits from patients seeking Medical services increased. |
|
Hong Kong & Macau Clinical healthcare services |
To provide service to self-paid patients, areas include: - Medical: general practice services. - Specialist service/consultation: cover 18 different specialities. - Dental: dental care, dental check up. Also provide services such as dental implants. - Auxiliary: Physiotherapy, vision & eye care. - Medical imaging - Laboratory services. |
Revenue of this segment increased by 28.1% from HK$213.1 million for 1HFY2021 to HK$273.0 million for 1HFY2022. The increase mainly due to health check-ups and the medical imaging as well as laborator business.
One point to note that specialist business as well as medical imaging business had been of the main contribution to this line of business, according to the group M&A analysis in 2021 annual report.
|
|
Mainland China healthcare business |
Businesses include: - Healthcare check-up business - Company owned clinic to provide outpatient services |
Revenue of this business line incresed by 29.9% from HK$17.5 million to HK$22.7 million.
* Part of the operation that engaged in corporation healthcare solutions as well as professional training of doctors and nurses in mainland China was disposed last year. |
Source: Company's annual reports and interim reports
The company's revenue had been growing steadily for the past seven years, the drop in year 2020 was attributed to the pandmeic. The growth was subsequently picked in year 2021. The company continued to re-adjust their business strategies through re-organising (Mainland China business) and acquistions (Medical imaging business etc). We expect that the company may continue to expand the medical imaging, laboratary services as well as specialist services since these areas had been one of the main revenue driver for the past few years.
投資涉及風險，有可能損失投資本金。你應諮詢專業人士，就本身的投資經驗、財務狀況、個人目標及風險取向，以提供投資意見。各類產品的風險，請參閱本公司網頁 http://www.phillip.com.hk《風險披露聲明》。
輝立（或其僱員) 可能持有本文所述有關的投資產品。此外，輝立（或任何附屬公司）隨時可能替向報告內容所述及的公司提供服務、招攬或業務往來。
以上資料為輝立擁有並受版權及知識產權法保護。除非事先得到輝立明確書面批准，否則不應複製、散播或發佈。
